CN1649645A - 用于治疗肾癌的缩酚肽 - Google Patents
用于治疗肾癌的缩酚肽 Download PDFInfo
- Publication number
- CN1649645A CN1649645A CNA038075938A CN03807593A CN1649645A CN 1649645 A CN1649645 A CN 1649645A CN A038075938 A CNA038075938 A CN A038075938A CN 03807593 A CN03807593 A CN 03807593A CN 1649645 A CN1649645 A CN 1649645A
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- formula
- salt
- kidney cancer
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
Claims (20)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36986802P | 2002-04-05 | 2002-04-05 | |
US60/369,868 | 2002-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1649645A true CN1649645A (zh) | 2005-08-03 |
Family
ID=28791999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA038075938A Pending CN1649645A (zh) | 2002-04-05 | 2003-03-27 | 用于治疗肾癌的缩酚肽 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8673888B2 (zh) |
EP (1) | EP1492596A1 (zh) |
JP (1) | JP2005521737A (zh) |
CN (1) | CN1649645A (zh) |
AU (1) | AU2003219555A1 (zh) |
CA (1) | CA2481466A1 (zh) |
MX (1) | MXPA04009761A (zh) |
TW (1) | TW200405817A (zh) |
WO (1) | WO2003084611A1 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04001612A (es) * | 2001-08-21 | 2004-07-08 | Fujisawa Pharmaceutical Co | Uso medicinal de inhibidor de la histona desacetilasa y metodo para evaluar el efecto antitumoral del mismo. |
US20080233562A1 (en) * | 2003-02-19 | 2008-09-25 | Astellas Pharma Inc. | Method of Estimating Antitumor Effect of Histone Deacetylase Inhibitor |
US20050059682A1 (en) * | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
MXPA06003222A (es) * | 2003-09-25 | 2006-05-22 | Astellas Pharma Inc | Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii. |
WO2005058298A2 (en) * | 2003-12-10 | 2005-06-30 | Wisconsin Alumni Research Foundation | Fk228 analogs and their use as hdac-inhibitors |
US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
ZA200800901B (en) | 2005-07-14 | 2010-05-26 | Takeda San Diego Inc | Histone deacetylase inhibitors |
CA2630216A1 (en) * | 2005-11-18 | 2007-05-31 | Gloucester Pharmaceuticals, Inc. | Metabolite derivatives of the hdac inhibitor fk228 |
CA2649877A1 (en) * | 2006-04-24 | 2007-12-21 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
WO2007146730A2 (en) | 2006-06-08 | 2007-12-21 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
AU2007342028B2 (en) | 2006-12-29 | 2013-06-13 | Celgene Corporation | Purifiction of romidepsin |
AU2007342030B2 (en) * | 2006-12-29 | 2013-08-15 | Celgene Corporation | Romidepsin-based treatments for cancer |
US8034768B2 (en) * | 2007-06-22 | 2011-10-11 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by histone deacetylase inhibitors |
CA2804795A1 (en) | 2010-07-12 | 2012-01-19 | Nicholas Vrolijk | Romidepsin solid forms and uses thereof |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8817743D0 (en) | 1988-07-26 | 1988-09-01 | Fujisawa Pharmaceutical Co | Fr901228 substance & preparation thereof |
JPH0764872A (ja) | 1993-08-26 | 1995-03-10 | Fujitsu Ten Ltd | データ記憶制御装置 |
JP4810784B2 (ja) | 2000-07-17 | 2011-11-09 | アステラス製薬株式会社 | 還元型fk228およびその用途 |
AR035659A1 (es) * | 2000-12-07 | 2004-06-23 | Hoffmann La Roche | Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos |
US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
MXPA04001612A (es) | 2001-08-21 | 2004-07-08 | Fujisawa Pharmaceutical Co | Uso medicinal de inhibidor de la histona desacetilasa y metodo para evaluar el efecto antitumoral del mismo. |
WO2003017763A1 (en) * | 2001-08-24 | 2003-03-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell |
EP2238982B8 (en) | 2003-06-27 | 2013-01-16 | Astellas Pharma Inc. | Therapeutic agent for soft tissue sarcoma |
MXPA06003222A (es) | 2003-09-25 | 2006-05-22 | Astellas Pharma Inc | Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii. |
US7951780B2 (en) | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
-
2003
- 2003-03-27 JP JP2003581847A patent/JP2005521737A/ja active Pending
- 2003-03-27 US US10/508,958 patent/US8673888B2/en active Active
- 2003-03-27 CA CA002481466A patent/CA2481466A1/en not_active Abandoned
- 2003-03-27 EP EP03715503A patent/EP1492596A1/en not_active Withdrawn
- 2003-03-27 CN CNA038075938A patent/CN1649645A/zh active Pending
- 2003-03-27 WO PCT/JP2003/003823 patent/WO2003084611A1/en active Application Filing
- 2003-03-27 AU AU2003219555A patent/AU2003219555A1/en not_active Abandoned
- 2003-03-27 MX MXPA04009761A patent/MXPA04009761A/es not_active Application Discontinuation
- 2003-04-04 TW TW092107689A patent/TW200405817A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2003219555A8 (en) | 2003-10-20 |
AU2003219555A1 (en) | 2003-10-20 |
EP1492596A1 (en) | 2005-01-05 |
WO2003084611A1 (en) | 2003-10-16 |
TW200405817A (en) | 2004-04-16 |
MXPA04009761A (es) | 2005-05-27 |
WO2003084611A8 (en) | 2004-04-08 |
JP2005521737A (ja) | 2005-07-21 |
CA2481466A1 (en) | 2003-10-16 |
US8673888B2 (en) | 2014-03-18 |
US20060135413A1 (en) | 2006-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1649645A (zh) | 用于治疗肾癌的缩酚肽 | |
ES2899372T3 (es) | Combinación de tratamiento del cáncer de próstata, composición farmacéutica y método de tratamiento | |
CN1189166A (zh) | 抑生长素肽 | |
CN1622805A (zh) | 包含止泻药和埃坡霉素或埃坡霉素衍生物的组合 | |
CN1228694A (zh) | 使用锰化合物降低抗肿瘤药物心脏毒性的方法 | |
CN1694711A (zh) | 扩大维生素剂量范围的方法 | |
CN1679631A (zh) | 用于治疗癌症的海鞘素743的组合物和用途 | |
CN113549129B (zh) | 一种d-构型抗肿瘤肽及其制备方法和应用 | |
CN1723034A (zh) | 治疗糖尿病的组合物和方法 | |
CN1917898B (zh) | 用于治疗间质肺部感染的血管活性肠肽的生物活性物质 | |
EA019738B1 (ru) | Профилактическое/терапевтическое средство против рака | |
TWI287986B (en) | Use of Epothilones for the treatment of the carcinoid syndrome | |
CN1678627A (zh) | 新的缩肽化合物 | |
CN1691943A (zh) | 利用g6976及其相关化合物进行肿瘤治疗 | |
CN1781932A (zh) | 阿霉素的衍生物及其制备方法和用途 | |
RU2002125463A (ru) | Полипептидное соединение, способы его получения, фармацевтическая композиция и способ профилактики или лечения грибковых заболеваний | |
CN1921891A (zh) | 连接到杯芳烃上的生长因子结合化合物 | |
JP3398255B2 (ja) | 新規ペプチド及びそれを有効成分とする骨疾患治療薬 | |
CN1886143A (zh) | 用于治疗癌症的包含锶、氨基酸和矿物物质的药剂及方法 | |
CN1294987C (zh) | 心肌肌钙蛋白i在制备抑制肿瘤药物中的应用 | |
CN1102047C (zh) | 一种新的肿瘤细胞多药耐药性逆转剂 | |
CN112094321A (zh) | His-Gly-Glu修饰的甲氨蝶呤,其合成,抗转移活性和应用 | |
WO2024057793A1 (ja) | 癌転移を抑制するシトルリン化ペプチド | |
CN1679914A (zh) | 还原型谷胱甘肽和依布硒啉的组合药物 | |
CN114605517A (zh) | 一种具有广谱抗癌作用的多肽lxp-7及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ASTELLAS PHARMA INC.; APPLICANT Free format text: FORMER OWNER: FUJISAWA PHARMACEUTICAL CO., LTD.; APPLICANT Effective date: 20060818 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060818 Address after: Tokyo, Japan Applicant after: Yamanouchi Pharma Co., Ltd. Co-applicant after: The United States of America, Represented by the Secretary, Department of Health Address before: Osaka Japan Applicant before: Fujisawa Pharmaceutical Co., Ltd. Co-applicant before: The United States of America, Represented by the Secretary, Department of Health |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20050803 |